Clinical Trials
61
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (45 trials with phase data)• Click on a phase to view related trials
News
RET Inhibitor Rechallenge Shows Promise in Pre-Treated NSCLC Patients After Toxicity-Related Discontinuation
Rechallenge with a different first-generation RET inhibitor after toxicity-related discontinuation achieved a 50% objective response rate and 9.89-month median progression-free survival in RET-rearranged NSCLC patients.
Johnson & Johnson's Pasritamig Shows Promising Anti-Tumor Activity in First-in-Human Prostate Cancer Trial
Johnson & Johnson announced first-in-human Phase 1 results for pasritamig, a novel bispecific T-cell engager targeting KLK2, showing promising anti-tumor activity in metastatic castration-resistant prostate cancer patients.
3D Printing Revolutionizes Drug Delivery Systems with Precision and Personalization
3D printing technology is emerging as a critical innovation in pharmaceutical manufacturing, enabling precise drug delivery systems with micron-level features that traditional manufacturing methods cannot achieve.
COSMIC-313 Trial: Triplet Therapy Shows Mixed Results in Advanced Renal Cell Carcinoma
Final analysis of COSMIC-313 phase 3 trial demonstrates sustained progression-free survival benefit with cabozantinib-nivolumab-ipilimumab combination in advanced RCC patients.
Phase 3 ESTIMABL2 Trial: Thyroidectomy Without Radioiodine Shows Noninferiority in Low-Risk Thyroid Cancer
Five-year analysis of ESTIMABL2 trial demonstrates thyroidectomy without radioiodine is noninferior to radioiodine administration in low-risk differentiated thyroid cancer, with event-free survival rates of 93.2% versus 94.8% respectively.
Hypofractionated Radiotherapy Shows Non-Inferior Lymphedema Risk in Early Breast Cancer
A phase 3 trial (HypoG-01) demonstrated that moderately hypofractionated locoregional radiation therapy is non-inferior to standard normofractionated radiation therapy for early breast cancer patients.